
"This is highly disappointing and and highly surprising."
So stated Orphazyme's Chief Financial Officer and interim CEO Anders Vadsholt following the company's Monday announcement that the phase II/III trial involving its main candidate, arimoclomol, as a treatment for the degenerative muscle disease inclusion body myositis (IBM) has not met its effect targets.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app